ライフサイエンスコーパス: apixaban

1 ant activity of dabigatran, rivaroxaban, and apixaban.

2 or dabigatran, 15 for rivaroxaban, and 4 for apixaban.

3 chronically anticoagulated with warfarin or apixaban.

4 e oral Factor Xa inhibitors, rivaroxaban and apixaban.

5 ficantly lower with dabigatran 110 mg BID or apixaban.

6 ents between the dabigatran (both doses) and apixaban.

7 he two factor Xa inhibitors, rivaroxaban and apixaban.

8 nitiated on VKA compared with rivaroxaban or apixaban.

9 jor bleeding events (MBEs) on rivaroxaban or apixaban.

10 gement of MBEs in patients on rivaroxaban or apixaban.

11 (95% CI, 87 to 94) among patients receiving apixaban.

12 on who received the 5 mg twice daily dose of apixaban.

13 rivaroxaban and of 30% among those receiving apixaban.

14 or life-threatening bleeding associated with apixaban.

15 risk in comparison with VKA was observed for apixaban (0.63, 0.51-0.77), edoxaban 60 mg (0.81, 0.67-0

16 ear in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.

17 primary efficacy outcome (relative risk with apixaban, 0.87; 95% confidence interval [CI], 0.62 to 1.

18 ts per 100 patient-years) (hazard ratio with apixaban, 0.95; 95% confidence interval [CI], 0.80 to 1.

19 were treated with NOACs (rivaroxaban 7,572, apixaban 1,066, and dabigatran 96).

20 7 patients; rivaroxaban, 54006 patients; and apixaban, 12886 patients), 4770 major bleeding events oc

21 279 of the 3705 patients (7.5%) assigned to apixaban (13.2 events per 100 patient-years) and in 293

22 2%), dabigatran (29%), rivaroxaban (13%), or apixaban (16%) were included with mean age (SD) 72.1 (11

23 Apixaban 2.5 mg twice daily (hazard ratio, 0.73; 95% con

24 Compared with placebo, apixaban 2.5 mg twice daily (hazard ratio, 1.78; 95% con

25 Seven patients received apixaban 2.5 mg twice daily for 8 days.

26 Apixaban 2.5 mg twice daily in patients on hemodialysis

27 nts (1.3%) who received at least one dose of apixaban (2.4 events per 100 patient-years) and in 18 of

28 double-blind study, we compared two doses of apixaban (2.5 mg and 5 mg, twice daily) with placebo in

29 ts per 100 patient-years) (hazard ratio with apixaban, 2.59; 95% CI, 1.50 to 4.46; P=0.001).

30 months of placebo (n=611) or 1 of 4 doses of apixaban: 2.5 mg twice daily (n=317), 10 mg once daily (

31 g NOACs (dabigatran 87, rivaroxaban 129, and apixaban 35) before their stroke, 1500 were taking warfa

32 ad similar efficacy with decreased bleeding; apixaban 5 mg B.I.D. reduced stroke, systemic embolism,

33 compare 4 therapies: dabigatran 150 mg BID, apixaban 5 mg BID, rivaroxaban 20 mg QD, and warfarin th

34 Patients were randomly assigned apixaban 5 mg twice daily (n=9120) or warfarin (target i

35 Apixaban 5 mg twice daily led to supratherapeutic levels

36 al flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target internatio

37 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin for at least 12 mo

38 ith a CHADS(2) score >/=3 dabigatran 150 mg, apixaban 5 mg, and rivaroxaban 20 mg resulted in statist

39 ), rivaroxaban (20 or 15 mg once daily), and apixaban (5 mg twice daily), respectively, were approved

40 The risk of death was similar with apixaban (54/4624 [1.17%]) and warfarin (49/4530 [1.08%]

41 3 patients (1.7%) who were receiving 5 mg of apixaban (a difference of 7.0 percentage points; 95% CI,

42 patients (1.7%) who were receiving 2.5 mg of apixaban (a difference of 7.2 percentage points; 95% con

43 The PT is less sensitive (especially for apixaban); a normal PT may not exclude clinically releva

44 illation) trial, and the treatment effect of apixaban according to NT-proBNP levels.

45 expected stay of at least 3 days to receive apixaban, administered orally at a dose of 2.5 mg twice

46 lood samples were collected before and after apixaban administration on days 1 and 8 (nondialysis day

47 A fixed-dose regimen of apixaban alone was noninferior to conventional therapy f

48 Apixaban also had lower major or clinically relevant ble

49 Apixaban, an oral direct factor Xa inhibitor, is a novel

50 Apixaban, an oral factor Xa inhibitor administered in fi

51 Apixaban, an oral factor Xa inhibitor that can be admini

52 Apixaban, an oral, direct factor Xa inhibitor, may reduc

53 1.01 per 100 patient-years of follow-up with apixaban and 1.23 with warfarin (HR 0.82, 95% CI 0.65 to

54 Total costs/patient were $3454 and $1805 for apixaban and aspirin in the trial-length and $44 232 and

55 drug levels of dabigatran, rivaroxaban, and apixaban and coagulation assay results.

56 here were no significant differences between apixaban and dabigatran 110 mg BID in safety endpoints.

57 bleeding," this was lower for treatment with apixaban and dabigatran compared with warfarin.

58 significant differences in efficacy between apixaban and dabigatran etexilate (both doses) or rivaro

59 cacy differences among the 3 drugs, although apixaban and dabigatran were numerically superior to riv

60 for VTE treatment in the United States, and apixaban and edoxaban are under regulatory consideration

61 coagulants (such as dabigatran, rivaroxaban, apixaban and edoxaban) offer relative efficacy, safety a

62 ng occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional

63 edian times to GI bleeding were <90 days for apixaban and rivaroxaban and <120 days for dabigatran.

64 The phase III trials of apixaban and rivaroxaban have completed enrollment and a

65 xanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants w

66 Apixaban and rivaroxaban were evaluated in phase III tri

67 -effectiveness most affected by the price of apixaban and the time horizon.

68 control and at a rate of 0.33% per year with apixaban and was associated with high short-term morbidi

69 overall, direct OAC (dabigatran/rivaroxaban/apixaban), and multivariable associations between clinic

70 ivaroxaban, 0.28% (95% CrI, 0.14%-0.50%) for apixaban, and 0.89% (95% CrI, 0.66%-1.16%) for the LMWH-

71 4 administering rivaroxaban, 2 administering apixaban, and 3 administering edoxaban) enrolling a tota

72 with VTE were initiated on VKA, rivaroxaban, apixaban, and dabigatran.

73 e effects of the anti-Xa NOACs (rivaroxaban, apixaban, and edoxaban), and a number of other anticoagu

74 ral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban), many have questioned the need f

75 ACs), which include dabigatran, rivaroxaban, apixaban, and edoxaban, are poised to replace warfarin f

76 ts (DOACs), such as dabigatran, rivaroxaban, apixaban, and edoxaban, provide potential advantages ove

77 This article focuses on rivaroxaban, apixaban, and edoxaban, the oral factor Xa inhibitors in

78 0 who received rivaroxaban, six who received apixaban, and one who received edoxaban.

79 major bleeding rates were low and similar in apixaban- and warfarin-treated patients, regardless of w

80 30 days was 43.3% with no difference between apixaban- and warfarin-treated patients.

81 For rivaroxaban and apixaban, anti-Xa activity is linear (R(2) = 0.89 to 1.0

82 f Long-Term Anticoagulation Therapy [RELY]), apixaban (Apixaban for Reduction in Stroke and Other Thr

83 ate and factor Xa inhibitors rivaroxaban and apixaban are new oral anticoagulants that are at least a

84 mbin (dabigatran) or factor Xa (rivaroxaban, apixaban) are effective and safe alternatives to vitamin

85 ulants, such as dabigatran, rivaroxaban, and apixaban, are emerging, but their relatively short half-

86 ccurred in 74/4560 (1.62%) procedures in the apixaban arm and 86/4454 (1.93%) in the warfarin arm (OR

87 Data Monitoring Committee, the 2 higher-dose apixaban arms were discontinued because of excess total

88 The benefits of apixaban as compared with warfarin are consistent regard

89 The superior efficacy and safety of apixaban as compared with warfarin were similar in patie

90 daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) and warfarin in patients w

91 daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) compared with treatment wi

92 Extended anticoagulation with apixaban at either a treatment dose (5 mg) or a thrombop

93 randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, fol

94 randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (

95 The addition of apixaban, at a dose of 5 mg twice daily, to antiplatelet

96 placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, i

97 aspirin; however, as follow-up was extended, apixaban became cost-effective and eventually dominant.

98 Major bleeding was significantly lower with apixaban compared with dabigatran 150 mg BID (by 26%) an

99 The benefits of apixaban compared with warfarin for stroke or systemic e

100 f stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial

101 e aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroup

102 The efficacy of apixaban compared with warfarin is independent of the NT

103 rly, the benefit of 5 mg twice daily dose of apixaban compared with warfarin on major bleeding in pat

104 ts in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and syste

105 The difference in major bleeding with apixaban compared with warfarin was 1.07 per 100 patient

106 Apixaban, compared with warfarin, was associated with fe

107 o-1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, compound 40).

108 cebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per millili

109 Apixaban consistently reduced stroke, mortality, and ble

110 Apixaban consistently reduced the rate of stroke and sys

111 Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are alternatives t

112 w of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban).

113 min K antagonist oral anticoagulants (NOACs) apixaban, dabigatran, edoxaban, and rivaroxaban are admi

114 tients with AF were identified who initiated apixaban, dabigatran, or rivaroxaban between October 1,

115 patients with atrial fibrillation evaluating apixaban, dabigatran, or rivaroxaban versus warfarin.

116 imed to compare 4 oral anticoagulant agents (apixaban, dabigatran, rivaroxaban, and warfarin) for the

117 bling of serum creatinine, and AKI; however, apixaban did not have a statistically significant relati

118 Dabigatran, rivaroxaban and apixaban differ from warfarin with their fixed oral dose

119 respectively, in Factor Xa-inhibited (250 nM apixaban), diluted platelet rich plasma that had been lo

120 administered 6-10 h after the surgery), and apixaban (dose of 2.5 mg twice daily, starting 12-24 h a

121 ived PCCs for the reversal of rivaroxaban or apixaban due to a MBE.

122 In Phase III trials, rivaroxaban, apixaban, edoxaban (antifactor Xa agents), and dabigatra

123 factor IIa (dabigatran) or Xa (rivaroxaban, apixaban, edoxaban) are available.

124 Insufficient published data for apixaban, edoxaban, and rivaroxaban indicate that furthe

125 ree are being evaluated in phase III trials (apixaban, edoxaban, and rivaroxaban) for the prevention

126 ministering rivaroxaban, and 3 administering apixaban) enrolling a total of 57,491 patients were incl

127 Dabigatran, rivaroxaban, and apixaban exhibit variable effects on coagulation assays.

128 initiating VKA, dabigatran, rivaroxaban, or apixaban for patients aged >/=85 years were 0.81 (95% CI

129 METHODS AND Apixaban for Prevention of Acute Ischemic and Safety Eve

130 ata from 48286 participants in 4 trials: the Apixaban for Prevention of Acute Ischemic Events 2 (APPR

131 s with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

132 with the use of amiodarone in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboemboli

133 The Apixaban for Reduction in Stroke and Other Thromboemboli

134 n 14 821 atrial fibrillation patients in the Apixaban for Reduction in Stroke and Other Thromboemboli

135 ntricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboemboli

136 In the Apixaban for Reduction in Stroke and Other Thromboemboli

137 The Apixaban for Reduction in Stroke and Other Thromboemboli

138 m Anticoagulation Therapy [RELY]), apixaban (Apixaban for Reduction in Stroke and Other Thromboemboli

139 The Apixaban for Reduction in Stroke and Other Thromboemboli

140 the overall trial population enrolled in the Apixaban for Reduction in Stroke and Other Thromboemboli

141 The prospective, randomized, double-blind Apixaban for Reduction in Stroke and Other Thromboemboli

142 In the Apixaban for Reduction of Stroke and Other Thromboemboli

143 with apixaban or warfarin in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With A

144 fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With A

145 gatran etexilate (2 doses), rivaroxaban, and apixaban for their relative efficacy and safety against

146 prescription of dabigatran, rivaroxaban, or apixaban from January 1, 2012, through December 31, 2016

147 dent exposure to dabigatran, rivaroxaban, or apixaban from October 1, 2010 through February 28, 2015.

148 had occurred in 0.47% of the patients in the apixaban group (15 of 3184 patients) and in 0.19% of the

149 atients who could be evaluated, 2.71% in the apixaban group (60 patients) and 3.06% in the enoxaparin

150 o group, as compared with 0.8% in the 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.

151 ain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group

152 or the primary efficacy outcome--2211 in the apixaban group and 2284 in the enoxaparin group.

153 46 per 100 patient-years of follow-up in the apixaban group and 3.24 in the warfarin group (hazard ra

154 te of major hemorrhage among patients in the apixaban group was 2.13% per year compared with 3.09% pe

155 .5% in the placebo group, 0.2% in the 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group.

156 .3% in the placebo group, 3.0% in the 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group.

157 hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the w

158 he primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the w

159 of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the w

160 ccurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in th

161 ding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the co

162 2.5-mg apixaban group, and 0.1% in the 5-mg apixaban group.

163 e 2.5-mg apixaban group and 0.5% in the 5-mg apixaban group.

164 2.5-mg apixaban group, and 4.2% in the 5-mg apixaban group.

165 Apixaban had a lower risk of association with GI bleedin

166 r rates of stroke and systemic embolism, but apixaban had a lower risk of major hemorrhage compared w

167 Patients who received apixaban had lower rates of major bleeding than did thos

168 Apixaban had the most favorable GI safety profile among

169 of patients receiving DOAC agents, we found apixaban had the most favorable GI safety profile and ri

170 INTERPRETATION: Because apixaban has benefits over warfarin that are consistent

171 he oral factor Xa inhibitors rivaroxaban and apixaban have entered late phase development for VTE thr

172 coagulants (NOACs) (rivaroxaban, dabigatran, apixaban) have been approved by international regulatory

173 s was significantly lower for treatment with apixaban (hazard ratio [HR], 0.35; 95% CI, 0.17-0.72) an

174 varoxaban (HR, 0.55; 95% CrI, 0.35-0.89) and apixaban (HR, 0.31; 95% CrI, 0.15-0.62) were associated

175 The benefits of apixaban in comparison with warfarin are consistent rega

176 Further testing of apixaban in patients at risk of recurrent ischemic event

177 le is known about the efficacy and safety of apixaban in relation to renal function changes over time

178 of an increase in major bleeding events with apixaban in the absence of a counterbalancing reduction

179 e was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfar

180 , with only the trials testing dabigatran or apixaban including few patients with 1 stroke risk facto

181 d 6.87 and 6.51 in the 10-year model, making apixaban inferior in the first model but dominant in the

182 Apixaban is a novel oral direct factor Xa inhibitor that

183 l Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke

184 ement of MBEs associated with rivaroxaban or apixaban is effective in most cases and is associated wi

185 conclusion the initiation of rivaroxaban and apixaban is increasing significantly over time in patien

186 The 5 mg twice daily dose of apixaban is safe, efficacious, and appropriate for patie

187 ajor extracranial hemorrhage associated with apixaban led to reduced hospitalization, medical or surg

188 On day 9, after a 2.5-mg dose, apixaban levels were monitored hourly during dialysis.

189 Apixaban lowered the risk of major bleeding (0.74; 0.60-

190 Apixaban lowers the risk of major and gastrointestinal b

191 effective strategy and that rivaroxaban and apixaban may be associated with the lowest risk for blee

192 The safety and efficacy of apixaban may vary depending on background antiplatelet t

193 ious stroke or TIA, the absolute benefits of apixaban might be greater in this population.

194 rval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage po

195 aller numbers of patients were observed with apixaban (n = 12) and dabigatran (n = 11).

196 The benefit of the 5 mg twice daily dose of apixaban (n = 8665) compared with warfarin (n = 8657) on

197 5 mg/dL or higher-received a reduced dose of apixaban of 2.5 mg twice daily.

198 sess the effect of treatment with aspirin or apixaban on ischemic stroke and major bleeding, in relat

199 poral trends in initiation of rivaroxaban or apixaban or dabigatran versus vitamin K antagonists (VKA

200 ts with AF were randomized to treatment with apixaban or warfarin in the ARISTOTLE (Apixaban for the

201 gned to receive the 5 mg twice daily dose of apixaban or warfarin, 3966 had 1 dose-reduction criterio

202 18 201 patients with atrial fibrillation to apixaban or warfarin.

203 , 18,201 patients with AF were randomized to apixaban or warfarin.

204 d 18201 patients with atrial fibrillation to apixaban or warfarin.

205 h one of the NOACs (rivaroxaban, dabigatran, apixaban) or VKA were identified between February 2012 a

206 compared dabigatran etexilate, rivaroxaban, apixaban, or edoxaban with VKA therapy in patients with

207 oral anticoagulant (dabigatran, rivaroxaban, apixaban, or edoxaban) with warfarin, and recorded event

208 oral thrombin inhibitor, and rivaroxaban and apixaban, oral factor Xa inhibitors, have been found to

209 ncrease in the initiation of rivaroxaban and apixaban (p-value for increasing trend, p < 0001).

210 We aimed to determine apixaban pharmacokinetics at steady state in patients on

211 Apixaban produced significantly fewer major hemorrhages

212 of $100 000 per quality-adjusted life year, apixaban provided the greatest absolute benefit while st

213 clinical relevance of reducing ICH by using apixaban rather than warfarin and avoiding concomitant a

214 Apixaban reduced rates of stroke, mortality, and bleedin

215 Apixaban reduced stroke, mortality, and bleeding regardl

216 Apixaban reduced the risk of both outcomes more than war

217 Compared with aspirin, apixaban reduces stroke risk in atrial fibrillation (AF)

218 Apixaban resulted in significantly less ICH (0.33% per y

219 Compared with warfarin, apixaban, rivaroxaban, and dabigatran, costs were $93 06

220 enzymes thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban, and edoxaban) and given in fixed

221 s of randomized trials of DOACs (dabigatran, apixaban, rivaroxaban, and edoxaban) for efficacy and bl

222 ratio [RR], 0.68 [95% CI, 0.21 to 2.23]) and apixaban (RR, 0.59 [CI, 0.26 to 1.33]) but increased maj

223 of $100 000 per quality-adjusted life year, apixaban seems to be the optimal anticoagulation strateg

224 FINDINGS: Apixaban significantly reduced stroke or systemic emboli

225 nial and fatal bleeding events occurred with apixaban than with placebo.

226 , and mortality were consistently lower with apixaban than with warfarin across center average TTR an

227 m inhibitors of coagulation (rivaroxaban and apixaban) than dabigatran which is a direct thrombin inh

228 ing the study drug) of patients treated with apixaban therapy and warfarin therapy were not statistic

229 To assess the cost and cost-effectiveness of apixaban therapy compared with warfarin therapy in patie

230 Apixaban therapy for ARISTOTLE-eligible patients with at

231 OTLE outcomes, was significantly longer with apixaban therapy vs warfarin therapy (7.94 vs 7.54 quali

232 Apixaban therapy vs warfarin therapy.

233 Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in pre

234 tion in ischemic events with the addition of apixaban to antiplatelet therapy in patients with recent

235 ectively included patients on rivaroxaban or apixaban treated with PCCs for the management of MBEs.

236 Among the apixaban-treated participants, anti-factor Xa activity w

237 urred after 16/4624 (0.35%) procedures among apixaban-treated patients and 26/4530 (0.57%) procedures

238 ity within 30 days occurred half as often in apixaban-treated patients than in those receiving warfar

239 e effectiveness with no benefit in safety in apixaban-treated patients with normal or mildly impaired

240 significant difference in major bleeding in apixaban-treated patients.

241 e interaction p values for amiodarone use by apixaban treatment effects were not significant.

242 s might be less relevant when used to tailor apixaban treatment to individual patients than they are

243 washout period, five patients received 5 mg apixaban twice daily for 8 days.

244 Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily.

245 Using the Apixaban versus Acetylsalicylic Acid to Prevent Stroke i

246 ALYs), and incremental cost-effectiveness of apixaban versus aspirin from the Medicare perspective.

247 The impact of apixaban versus aspirin on ischemic stroke and major ble

248 re was also no significant heterogeneity for apixaban versus aspirin with regard to major bleeding, w

249 ought to determine the cost-effectiveness of apixaban versus aspirin.

250 There were no significant differences for apixaban versus dabigatran (both doses) or rivaroxaban;

251 ients with atrial fibrillation randomised to apixaban versus warfarin in the ARISTOTLE trial and exte

252 he rate of stroke and systemic embolism with apixaban versus warfarin was 0.77 per 100 patient-years

253 The effects of apixaban versus warfarin were consistent in patients wit

254 Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.

255 n vs dabigatran for 31,574 patients, data on apixaban vs dabigatran for 13,084 patients, and data on

256 dabigatran for 13,084 patients, and data on apixaban vs rivaroxaban for 13,130 patients.

257 Interactions between the effects of apixaban vs warfarin and the presence of 1 or no dose-re

258 t benefits with the 5 mg twice daily dose of apixaban vs warfarin compared with patients without thes

259 The beneficial effects of apixaban vs warfarin on rates of stroke or systemic embo

260 ith apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89

261 Among the drugs studied, the OR for apixaban was 1.23 (95% CI, 0.56-2.73), the OR for dabiga

262 tive, although warfarin would be superior if apixaban was 2% less effective than expected.

263 tion (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2

264 Apixaban was associated with a lower risk of GI bleeding

265 Apixaban was associated with significantly more major bl

266 In our trial-length model, apixaban was more costly and no more effective than aspi

267 Apixaban was noninferior to conventional therapy (P<0.00

268 n extended course of thromboprophylaxis with apixaban was not superior to a shorter course with enoxa

269 Apixaban was shown to reduce the risk of major hemorrhag

270 In an atrial fibrillation population, apixaban was superior to aspirin for stroke prevention,

271 In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke o

272 Apixaban was the most used OAC at study end (41%), in pa

273 Although apixaban was the optimal strategy in our base case, in p

274 or treatment efficacy on ischemic stroke for apixaban when subdivided by stroke risk strata, based on

275 We report a case of a patient receiving apixaban who developed a spontaneous subdural hematoma a

276 as associated with upstart of rivaroxaban or apixaban with reference to age <65 within the specific a

277 When comparing apixaban with warfarin, patients who received amiodarone

278 ial Fibrillation (ARISTOTLE) trial comparing apixaban with warfarin.

279 hypothesized that extended prophylaxis with apixaban would be safe and more effective than short-ter

280 Probabilistic sensitivity analysis suggested apixaban would only be a cost-effective alternative (<$5